| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 25.55B | 26.18B | 26.64B | 24.13B | 22.24B | 12.94B |
| Gross Profit | 13.85B | 14.39B | 15.04B | 13.91B | 11.65B | 5.23B |
| EBITDA | 1.24B | 1.54B | 1.93B | 1.65B | 985.05M | -6.40B |
| Net Income | 125.84M | 314.02M | 619.81M | 168.09M | 477.68M | -5.42B |
Balance Sheet | ||||||
| Total Assets | 20.06B | 21.33B | 23.20B | 22.99B | 24.58B | 26.14B |
| Cash, Cash Equivalents and Short-Term Investments | 3.36B | 4.57B | 5.16B | 5.41B | 6.12B | 6.72B |
| Total Debt | 8.13B | 8.17B | 9.17B | 9.73B | 10.74B | 11.04B |
| Total Liabilities | 14.12B | 15.06B | 16.96B | 17.12B | 18.66B | 20.58B |
| Stockholders Equity | 5.94B | 6.27B | 6.24B | 5.87B | 5.93B | 5.57B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 385.33M | 692.34M | 729.38M | -509.50M | -4.92B |
| Operating Cash Flow | 0.00 | 926.34M | 1.22B | 1.10B | -247.82M | -4.49B |
| Investing Cash Flow | 0.00 | -198.47M | -591.36M | -502.14M | 132.52M | -400.64M |
| Financing Cash Flow | 0.00 | -1.31B | -915.08M | -1.32B | -486.78M | 7.49B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | ¥10.48B | 207.75 | ― | 5.06% | 0.36% | 81.58% | |
64 Neutral | ¥1.71B | 13.91 | ― | 2.62% | 11.55% | 28.89% | |
61 Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% | |
58 Neutral | ¥34.07B | 25.08 | ― | 2.48% | -4.39% | 31.40% | |
57 Neutral | ¥1.97B | 11.75 | ― | ― | 8.17% | 37.03% | |
54 Neutral | ¥3.92B | -3.24 | ― | ― | -4.35% | -132.57% | |
47 Neutral | ¥2.66B | 335.28 | ― | ― | -6.45% | 99.39% |
ESCRIT Inc. reported a decline in its financial performance for the six months ended September 30, 2025, with net sales dropping by 9.1% compared to the previous year. The company experienced a significant operating loss, reflecting challenges in its market environment. Despite the downturn, ESCRIT has revised its financial forecast for the fiscal year ending March 31, 2026, indicating expectations of a slight recovery in net sales and operating profit, albeit still projecting a net loss.
The most recent analyst rating on (JP:2196) stock is a Hold with a Yen184.00 price target. To see the full list of analyst forecasts on ESCRIT Inc. stock, see the JP:2196 Stock Forecast page.